Clinical utility of the oral JAK inhibitor tofacitinib in the treatment of rheumatoid arthritis

Journal of Inflammation Research

Volumn 6, Issue 1, 2013, Pages 129-136

  Cutolo, Maurizio ^a   Meroni, Marianna ^a  

^a UNIVERSITY OF GENOA   (Italy)

Author keywords

Intracellular signaling; Janus kinase inhibitors; Kinases; Rheumatoid arthritis; Small molecules inhibitors; Tofacitinib

Indexed keywords

ADALIMUMAB; C REACTIVE PROTEIN; CYTOKINE; CYTOKINE RECEPTOR; DISEASE MODIFYING ANTIRHEUMATIC DRUG; INTERLEUKIN 1; INTERLEUKIN 6; JANUS KINASE; JANUS KINASE 1; JANUS KINASE 2; JANUS KINASE 3; JANUS KINASE INHIBITOR; METHOTREXATE; MITOGEN ACTIVATED PROTEIN KINASE P38; PLACEBO; PROTEIN KINASE SYK; PROTEIN KINASE TYK2; STAT PROTEIN; TOFACITINIB; TUMOR NECROSIS FACTOR ALPHA;

ADAPTIVE IMMUNITY; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; B LYMPHOCYTE ACTIVATION; BRONCHITIS; CELL ACTIVITY; CELL DIFFERENTIATION; CELL INFILTRATION; CELL MATURATION; CELL PROLIFERATION; CELL SURVIVAL; CHOLESTEROL BLOOD LEVEL; CREATININE BLOOD LEVEL; CYTOKINE PRODUCTION; CYTOPLASM; DIARRHEA; DISEASE ACTIVITY; DOSE RESPONSE; DRUG BINDING; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG HALF LIFE; DRUG POTENCY; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; DRUG TOLERANCE; ENZYME ACTIVITY; ERYTHROCYTE SEDIMENTATION RATE; EXPERIMENTAL MODEL; GENE EXPRESSION; HEADACHE; HEMATOPOIESIS; HUMAN; HYPERLIPIDEMIA; IMMUNOCOMPETENT CELL; INFLAMMATORY CELL; INNATE IMMUNITY; INTRACELLULAR SIGNALING; LIPID BLOOD LEVEL; LUNG TUBERCULOSIS; MAXIMUM PLASMA CONCENTRATION; MEDIATOR; METABOLIC CLEARANCE RATE; MONOTHERAPY; NATURAL KILLER CELL; NONHUMAN; PATHOGENESIS; PATHOPHYSIOLOGY; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROTEIN BINDING; PROTEIN BLOOD LEVEL; PROTEIN FUNCTION; PSORIASIS; PSORIASIS VULGARIS; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RHEUMATOID ARTHRITIS; RHINOPHARYNGITIS; SIDE EFFECT; SYNOVIUM; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; TREATMENT DURATION; TREATMENT OUTCOME; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION;

EID: 84887684033     PISSN: None     EISSN: 11787031     Source Type: Journal    
DOI: 10.2147/JIR.S35901     Document Type: Review

References (37)

1. McInnes IB, Schett G. The pathogenesis of rheumatoid arthritis. N Engl J Med. 2011;365(23):2205-2219.
2. Emery P, Dörner T. Optimising treatment in rheumatoid arthritis: a review of potential biological markers of response. Ann Rheum Dis. 2011;70(12):2063-2070.
3. Weinblatt ME, Trentham DE, Fraser PA, et al. Long-term prospective trial of low-dose methotrexate in rheumatoid arthritis. Arthritis Rheum. 1988;31(2):167-175.
4. Cutolo M. The kinase inhibitor tofacitinib in patients with rheumatoid arthritis: latest findings and clinical potential. Ther Adv Musculoskelet Dis. 2013;5(1):3-11.
5. Fleischmann R. Novel small-molecular therapeutics for rheumatoid arthritis. Curr Opin Rheumatol. 2012;24(3):335-341.
6. Salgado E, Maneiro JR, Carmona L, Gomez-Reino JJ. Safety profile of protein kinase inhibitors in rheumatoid arthritis: systematic review and meta-analysis. Ann Rheum Dis. Epub April 18, 2013.
7. Leonard WJ. Role of Jak kinases and STATs in cytokine signal transduction. Int J Hematol. 2001;73(3):271-277.
8. Ghoreschi K, Jesson MI, Li X, et al. Modulation of innate and adaptive immune responses by tofacitinib (CP-690,550). J Immunol. 2011;186(7):4234-4243.
9. Cheng H, Ross JA, Frost JA, Kirken RA. Phosphorylation of human Jak3 at tyrosines 904 and 939 positively regulates its activity. Mol Cell Biol. 2008;28(7):2271-2282.
10. Funakoshi-Tago M, Tago K, Kasahara T, Parganas E, Ihle JN. Negative regulation of Jak2 by its auto-phosphorylation at tyrosine 913 via the Epo signaling pathway. Cell Signal. 2008;20(11):1995-2001.
11. Karaman M W, Herrgard S, Treiber DK, et al. A quantitative analysis of kinase inhibitor selectivity. Nat Biotechnol. 2008;26(1):127-132.
12. Ingley E, Klinken S P. Cross-regulation of JAK and Src kinases. Growth Factors. 2006;24(1):89-95.
13. Yokota A, Narazaki M, Shima Y, et al. Preferential and persistent activation of the STAT1 pathway in rheumatoid synovial fluid cells. J Rheumatol. 2001;28(9):1952-1959.
14. Kasperkovitz P V, Verbeet NL, Smeets TJ, et al. Activation of the STAT1 pathway in rheumatoid arthritis. Ann Rheum Dis. 2004;63(3): 233-239.
15. Levy DE, Lee CK. What does Stat3 do? J Clin Invest. 2002;109(9): 1143-1148.
16. Oshea JJ. Targeting the Jak/STAT pathway for immunosuppression. Ann Rheum Dis. 2004;63 Suppl 2:267-271.
17. Tanaka Y, Maeshima K, Maeshima Y, Yamaoka K. In vitro and in vivo analysis of a JAK inhibitor in rheumatoid arthritis. Ann Rheum Dis. 2012;71 Suppl 2:170-174.
18. Riese RJ, Krishnaswami S, Kremer J. Inhibition of JAK kinases in patients with rheumatoid arthritis: scientifc rationale and clinical outcomes. Best Pract Res Clin Rheumatol. 2010;24(4):513-526.
19. Bannwarth B, Kostine M, Poursac N. A pharmacokinetic and clinical assessment of tofacitinib for the treatment of rheumatoid arthritis. Expert Opin Drug Metab Toxicol. 2013;9(6):753-761.
20. Rakieh C, Conaghan PG. Tofacitinib for treatment of rheumatoid arthritis. Adv Ther. 2013;30(8):713-726.
21. Habib T, Senadheera S, Weinberg K, Kaushansky K. The common gamma chain (gamma c) is a required signaling component of the IL-21 receptor and supports IL-21-induced cell proliferation via JAK3. Biochemistry. 2002;41(27):8725-8731.
22. Kremer JM, Bloom BJ, Breedveld FC, et al. The safety and efficacy of a JAK inhibitor in patients with active rheumatoid arthritis: Results of a double-blind, placebo-controlled phase IIa trial of three dosage levels of CP-690,550 versus placebo. Arthritis Rheum. 2009;60(7): 1895-1905.
23. Tanaka Y, Takeuchi T, Yamanaka H, et al. Tofacitinib (CP-690,550), an oral Janus kinase inhibitor, as monotherapy in Japanese patients with active rheumatoid arthritis: a 12-week Phase 2b study. Arthritis Rheum. 2011;63(S10):2192.
24. Fleischmann R, Cutolo M, Genovese MC, et al. Phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) or adalimumab monotherapy versus placebo in patients with active rheumatoid arthritis with an inadequate response to disease-modifying antirheumatic drugs. Arthritis Rheum. 2012;64(3):617-629.
25. Tanaka Y, Suzuki M, Nakamura H, Toyoizumi S, Zwillich SH; Tofacitinib Study Investigators. Phase II study of tofacitinib (CP-690,550) combined with methotrexate in patients with rheumatoid arthritis and an inadequate response to methotrexate. Arthritis Care Res (Hoboken). 2011;63(8):1150-1158.
26. Kremer JM, Cohen S, Wilkinson BE, et al. A phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) versus placebo in combination with background methotrexate in patients with active rheumatoid arthritis and an inadequate response to methotrexate alone. Arthritis Rheum. 2012;64(4):970-981.
27. Mamolo C, Harness J, Tan H, Menter A. Tofacitinib (CP-690,550), an oral Janus kinase inhibitor, improves patient-reported outcomes in a phase 2b, randomized, double-blind, placebo-controlled study in patients with moderate-to-severe psoriasis. J Eur Acad Dermatol Venereol. Epub January 7, 2013.
28. van Vollenhoven R F, Fleischmann R, Cohen S, et al; ORAL Standard Investigators. Tofacitinib or adalimumab versus placebo in rheumatoid arthritis. N Engl J Med. 2012;367(6):508-519.
29. Fleischmann R, Kremer J, Cush J, et al; ORAL Solo Investigators. Placebo-controlled trial of tofacitinib monotherapy in rheumatoid arthritis. N Engl J Med. 2012;367(6):495-507.
30. van der Heijde D, Tanaka Y, Fleischmann R, et al; ORAL Scan Investigators. Tofacitinib (CP-690,550) in patients with rheumatoid arthritis receiving methotrexate: twelve-month data from a twenty-four-month phase III randomized radiographic study. Arthritis Rheum. 2013;65(3):559-570.
31. Burmester GR, Blanco R, Charles-Schoeman C, et al; ORAL Step investigators. Tofacitinib (CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: a randomised phase 3 trial. Lancet. 2013;381(9865):451-460.
32. Leah E. Clinical trials: Phase III trial results for tofacitinib bring new oral DMARD therapy a step closer for patients with rheumatoid arthritis. Nat Rev Rheumatol. 2012;8(10):561.
33. Kremer J, Zerbini C, Lee EB, et al. Tofacitinib (CP-690,550), an oral Janus kinase inhibitor: analyses of efficacy endpoints by subgroups in a pooled phase 2 and 3 rheumatoid arthritis study population. Ann Rheum Dis. 2012;71(Suppl 3):203-207.
34. Kawalec P, Mikrut A, Wisńiewska N, Pilc A. The effectiveness of tofacitinib, a novel Janus kinase inhibitor, in the treatment of rheumatoid arthritis: a systematic review and meta-analysis. Clin Rheumatol. 2013;32(10):1415-1424.
35. Garber K. Pfzer's first-in-class JAK inhibitor pricey for rheumatoid arthritis market. Nat Biotechnol. 2013;31(1):3-4.
36. Refusal of the marketing authorization for Xeljanz (tofacitinib). EMA/460814/2013. Available from http://www.ema.europa.eu/docs/en_GB/document_library/Summary_of_opinion_-_authorisation/human/002542/WC500146629.pdf. Accessed November 5, 2013.
37. Walsh N [webpage on the Internet]. Pfzer oral RA drug gets FDA approval. Little Falls, NJ: MedPage Today, LLC; 2012. Available from: http://www.medpagetoday.com/Rheumatology/Arthritis/35799. Accessed January 11, 2013.